Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.
|09/05/17||Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit|
|COPENHAGEN, Denmark, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing in the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) of the opening brief for the appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent.
“We continue to believe that our intellectual property is strong and that ... |
|09/01/17||Forward Pharma Board of Directors Approves Capital Reduction and Returns EUR 917.7 Million to Shareholders|
|COPENHAGEN, Denmark, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the final approval by the Company’s board of directors of the plans to return a total of EUR 917.7 million to its shareholders through a capital reduction (the “Capital Reduction”).
On September 1, 2017, following this approval, the Company effected the Capital Reduction with a distribution of proceeds to holders of ordinary shares. The record date for holders... |
|08/02/17||Forward Pharma Obtains Shareholder Approval of the Planned Capital Reduction at the Extraordinary General Meeting|
|COPENHAGEN, Denmark, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the result of the extraordinary general meeting of its shareholders held on August 2, 2017 (the “Extraordinary General Meeting”), where the requisite majority of the votes cast approved the plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction (the “Capital Reduction”).
Forward has received... |
|07/18/17||Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders|
|COPENHAGEN, Denmark, July 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction. This decision is based on a careful evaluation of the most appropriate capital allocation strategy after receipt of the non-refundable USD 1.25 billion cash fee from Biogen. The capital reduction aligns the amount of working capital with t... |
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.|